静脉对乙酰氨基酚能否减少儿童急诊镰状细胞危象的阿片需求?
这项前瞻性随机双盲安慰剂对照试验在学术城市儿童急诊科纳入4至16岁镰状细胞病血管闭塞危象疼痛患者,所有患者接受静脉吗啡0.1 mg/kg、酮咯酸0.5 mg/kg或两者,随机接受静脉对乙酰氨基酚15 mg/kg或安慰剂,每30分钟重新评估是否需要追加阿片至最多三次。共71例随机,对乙酰氨基酚组35例和对照组36例分析,两组基线特征和初始疼痛评分相似。对乙酰氨基酚组平均总吗啡量8.6 mg(95%CI 6.5-10.8)与安慰剂组8.0 mg(95%CI 5.9-10.2)无显著差异,平均累积吗啡剂量两组均为0.2 mg/kg(95%CI 0.1-0.2),离开急诊时平均疼痛评分对乙酰氨基酚组5.5(95%CI 4.3-6.6)与安慰剂组5.2(95%CI 4.2-6.3)相当,入院率、72小时返诊率和不良事件无临床或统计学显著差异。结论认为静脉对乙酰氨基酚与吗啡联用不提供阿片节俭效应。
要点
- 在4至16岁镰状细胞病血管闭塞危象患儿中,静脉对乙酰氨基酚15 mg/kg未减少吗啡总用量:对乙酰氨基酚组8.6 mg vs 安慰剂组8.0 mg(95%CI分别6.5-10.8和5.9-10.2)。
- 两组累积吗啡剂量均为0.2 mg/kg(95%CI 0.1-0.2),无差异。
- 离开急诊时疼痛评分对乙酰氨基酚组5.5(95%CI 4.3-6.6)vs 安慰剂组5.2(95%CI 4.2-6.3),等效。
- 入院率、72小时返诊率和不良事件两组无临床或统计学显著差异。
- 结论:静脉对乙酰氨基酚作为吗啡辅助用药在儿童镰状细胞危象中不提供阿片节俭效应。
适用人群与场景
- 纳入:4至16岁镰状细胞病(SCD)伴血管闭塞危象(VOC)疼痛的儿童急诊患者。
- 场景:学术城市儿童急诊科(ED)。
- 所有患者均接受静脉吗啡0.1 mg/kg、酮咯酸0.5 mg/kg或两者。
诊断标准与关键阈值
- 诊断标准:镰状细胞病血管闭塞危象疼痛(原文未提供具体诊断界值)。
- 疼痛再评估:每30分钟评估是否需要追加阿片剂量,最多三次。
处置流程与药物剂量
- 第一步:所有患者接受静脉吗啡0.1 mg/kg、酮咯酸0.5 mg/kg或两者。
- 第二步:随机给予静脉对乙酰氨基酚15 mg/kg或安慰剂。
- 第三步:每30分钟重新评估,按需追加阿片剂量至最多三次。
- 监测:总吗啡量、疼痛评分、入院率、72小时返诊率、不良事件。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:前瞻性、随机、双盲、安慰剂对照试验;样本量71例随机(对乙酰氨基酚组35例,对照组36例分析);单中心(学术城市儿童急诊科);人群为4至16岁SCD伴VOC疼痛患者。
- 干预与对照:所有患者接受静脉吗啡0.1 mg/kg、酮咯酸0.5 mg/kg或两者,随机加用静脉对乙酰氨基酚15 mg/kg或安慰剂。
- 主要终点:平均总吗啡量对乙酰氨基酚组8.6 mg(95%CI 6.5-10.8)vs 安慰剂组8.0 mg(95%CI 5.9-10.2),无显著差异;平均累积吗啡剂量两组均为0.2 mg/kg(95%CI 0.1-0.2)。
- 关键次要终点:离开急诊时平均疼痛评分对乙酰氨基酚组5.5(95%CI 4.3-6.6)vs 安慰剂组5.2(95%CI 4.2-6.3);入院率、72小时返诊率和不良事件两组无临床或统计学显著差异。
证据类型、等级与局限
- 证据类型:随机双盲安慰剂对照试验(RCT)。
- 证据等级或推荐强度:原文未提及。
- 局限:原文未述局限性。
对床旁实践的改变
- 对于4至16岁镰状细胞病血管闭塞危象的急诊患儿,在给予静脉吗啡0.1 mg/kg和/或酮咯酸0.5 mg/kg的基础上加用静脉对乙酰氨基酚15 mg/kg,不能减少吗啡总用量。
- 静脉对乙酰氨基酚不改变离开急诊时的疼痛评分、入院率、72小时返诊率或不良事件。
- 该研究结果提示需进一步寻找辅助性非成瘾性止痛药(原文结论)。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: We evaluated the ability of intravenous (IV) acetaminophen to reduce the amount of opioid medication administered in pediatric patients with sickle cell disease (SCD) having vasoocclusive crisis (VOC) in an emergency department (ED) setting.
METHODS: This was a prospective, randomized, double-blind placebo-controlled trial at an academic urban pediatric ED. Participants included patients with SCD, aged 4 to 16 years, with VOC pain. All patients received a 0.1 mg/kg dose of IV morphine, 0.5 mg/kg ketorolac, or both. Patients were randomized to receive either 15 mg/kg IV acetaminophen or placebo. Patients were reassessed every 30 minutes to see whether additional opioid doses were indicated to a maximum of three doses. The total morphine given, pain scores, rates of admissions, 72-hour return visits, and adverse events were assessed for each group.
RESULTS: Of 71 subjects randomized, 35 patients in the acetaminophen group and 36 patients in the control group were analyzed. Baseline characteristics and initial pain scores were similar in both groups. The mean total amount of morphine given was 8.6 mg (95% confidence interval [CI] = 6.5 to 10.8) in the acetaminophen group and 8.0 mg (95% CI = 5.9 to 10.2) in the placebo group. The mean total cumulative morphine dosing was 0.2 mg/kg (95% CI = 0.1 to 0.2 mg/kg) in the acetaminophen group and 0.2 mg/kg (95% CI = 0.1 to 0.2 mg/kg) in the control group. The mean pain score at time of disposition was 5.5 (95% CI = 4.3 to 6.6) in the acetaminophen group and 5.2 (95% CI = 4.2 to 6.3) in the placebo group. There were no clinical or statistically significant differences between the rates of admission, 72-hour return visits, or adverse events.
CONCLUSION: In this study, patients who received IV acetaminophen did not receive less morphine than patients in the placebo group. Disposition pain scores for the two groups were also equivalent. We conclude that IV acetaminophen, when used in addition to morphine for pediatric sickle cell VOC pain, does not provide an opioid-sparing effect. Further searches for adjunctive nonaddictive pain medicines are indicated.
参考来源
- Dhebaria T, Sivitz A, Tejani C, et al. Does Intravenous Acetaminophen Reduce Opioid Requirement in Pediatric Emergency Department Patients With Acute Sickle Cell Crises? Acad Emerg Med. 2020. PMID: 33025690. doi:10.1111/acem.14149
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。